Introduction to SLU-PP-332
SLU-PP-332 binds to ERRα, ERRβ, and ERRγ, nuclear receptors involved in regulating genes linked to energy metabolism in tissues such as skeletal muscle, liver, heart, and brain. Unlike classical estrogen receptors, ERRs are orphan receptors with no identified natural ligand. Upon receptor activation, SLU-PP-332 influences several metabolic pathways:
Mitochondrial Biogenesis: Enhances expression of mitochondrial transcription factors, increasing mitochondrial content and oxidative capacity.
Fatty Acid Metabolism: Upregulates enzymes promoting fatty acid uptake and β-oxidation, shifting cellular energy usage toward fat metabolism.
Glucose Metabolism: Modulates glucose transporter and kinase signaling pathways, impacting glucose uptake and utilization.
Exercise-Mimetic Effects: Alters muscle fiber composition and endurance markers consistent with aerobic exercise adaptations.
Key Research Areas of SLU-PP-332
In animal models, SLU-PP-332 administration has been associated with:
Increased energy expenditure and improved metabolic markers.
Reduction in fat mass under diet-induced obesity conditions.
Enhanced exercise endurance capacity.
Improved mitochondrial respiration and muscle fiber type modulation.
Pharmacokinetic studies indicate moderate oral bioavailability and distribution to metabolically active tissues. Metabolism primarily occurs via hepatic enzymes.
Certificate of Analysis
The following technical details outline the properties of SLU-PP-332, based on available data.
Property | Description |
|---|---|
Chemical Name | (E)-4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide |
CAS Number | 303760-60-3 |
Molecular Formula | C18H14N2O2 |
Molecular Weight | 290.32 g/mol |
Appearance | White tablet |
Research Use Only
SLU-PP-332 is intended solely for laboratory research and in vitro or in vivo preclinical studies. It is not approved for human or veterinary use, nor for diagnostic, therapeutic, or cosmetic purposes. Misuse or mislabeling as a drug, supplement, or food is prohibited.
